-
Product Insights
Diabetic Foot Ulcers: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diabetic Foot Ulcers - Global Clinical Trials Review, 2026" provides an overview of Diabetic Foot Ulcers Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Product Insights
Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Macular Edema - Global Clinical Trials Review, 2025" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diabetic Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Nephropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Type 1 Diabetes in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033. This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report...
-
Sector Analysis
Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033. GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period. Major drivers of T1D market growth over...
-
Sector Analysis
Type 1 Diabetes Epidemiology Analysis and Forecast to 2033
Type 1 Diabetes Epidemiology Report Overview In the 7MM, there were 3,012,498 diagnosed prevalent cases of Type 1 Diabetes Epidemiology in 2023. The market will register an AGR of less than 1% during 2023-2033. Type 1 diabetes (T1D), formally referred to as insulin-dependent diabetes or juvenile diabetes, is a chronic autoimmune disease that predominantly develops in childhood and young adulthood and accounts for approximately 5–10% of all diabetes cases. It is caused by the body’s immune system destroying pancreatic beta...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.